Nancy A McNamara1, Marianne Gallup1, Travis C Porco2. 1. Francis I. Proctor Foundation, University of California San Francisco, San Francisco, California, United States. 2. Francis I. Proctor Foundation, University of California San Francisco, San Francisco, California, United States Department of Ophthalmology, University of California San Francisco, San Francisco, California, United States Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States.
Abstract
PURPOSE: Sjögren's syndrome (SS) is a common autoimmune disease that can cause aqueous-deficient dry eye and the aberrant differentiation of ocular mucosal epithelial cells toward a lineage that is pathologically keratinized and skin-like. PAX6 is the master regulator of corneal lineage commitment. Recently, we showed a functional role for PAX6 in preventing ocular surface damage induced by the proinflammatory cytokine, IL-1β, in a mouse model of SS. Here, we examine PAX6's potential as a clinical biomarker that predicts ocular surface disease in SS patients. METHODS: Impression cytology specimens isolated from the bulbar conjunctiva of control (n = 43) and SS patients (n = 43) were used to evaluate the relative abundance of PAX6, IL-1β, and pathologic keratinization marker, small proline-rich protein (SPRR1B) by TaqMan qPCR. Transcript expression was examined relative to clinical data, including the ocular staining score (OSS), tear breakup time (TBUT), Schirmer tear test, serum autoantibody results, and the labial salivary gland focus score. RESULTS: PAX6 expression was significantly reduced in SS patients (P = 0.010, Wilcoxon rank sum test), and highly correlated with OSS (Spearman ρ = 0.239, 95% CI 0.02-0.43; P = 0.027). The extent to which PAX6 predicted SPRR1B was largely dependent on IL-1β expression (R(2) = 0.28, P < 0.01) and elevated IL-1β predicted reduced TBUT (R(2) = 0.24, P = 0.035), low tear secretion (R(2) = 0.30, P = 0.011), and focus score (R(2) = 0.21, P = 0.002). CONCLUSIONS: Downregulation of PAX6 in SS patients was highly associated with ocular surface damage and largely dependent on the level of inflammation. Restoration of PAX6 may provide a clinical approach to manage dry eye in SS patients. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: Sjögren's syndrome (SS) is a common autoimmune disease that can cause aqueous-deficient dry eye and the aberrant differentiation of ocular mucosal epithelial cells toward a lineage that is pathologically keratinized and skin-like. PAX6 is the master regulator of corneal lineage commitment. Recently, we showed a functional role for PAX6 in preventing ocular surface damage induced by the proinflammatory cytokine, IL-1β, in a mouse model of SS. Here, we examine PAX6's potential as a clinical biomarker that predicts ocular surface disease in SS patients. METHODS: Impression cytology specimens isolated from the bulbar conjunctiva of control (n = 43) and SS patients (n = 43) were used to evaluate the relative abundance of PAX6, IL-1β, and pathologic keratinization marker, small proline-rich protein (SPRR1B) by TaqMan qPCR. Transcript expression was examined relative to clinical data, including the ocular staining score (OSS), tear breakup time (TBUT), Schirmer tear test, serum autoantibody results, and the labial salivary gland focus score. RESULTS:PAX6 expression was significantly reduced in SS patients (P = 0.010, Wilcoxon rank sum test), and highly correlated with OSS (Spearman ρ = 0.239, 95% CI 0.02-0.43; P = 0.027). The extent to which PAX6 predicted SPRR1B was largely dependent on IL-1β expression (R(2) = 0.28, P < 0.01) and elevated IL-1β predicted reduced TBUT (R(2) = 0.24, P = 0.035), low tear secretion (R(2) = 0.30, P = 0.011), and focus score (R(2) = 0.21, P = 0.002). CONCLUSIONS: Downregulation of PAX6 in SS patients was highly associated with ocular surface damage and largely dependent on the level of inflammation. Restoration of PAX6 may provide a clinical approach to manage dry eye in SS patients. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
Authors: Troy E Daniels; Darren Cox; Caroline H Shiboski; Morten Schiødt; Ava Wu; Hector Lanfranchi; Hisanori Umehara; Yan Zhao; Stephen Challacombe; Mi Y Lam; Yvonne De Souza; Julie Schiødt; Helena Holm; Patricia A M Bisio; Mariana S Gandolfo; Toshioki Sawaki; Mengtao Li; Wen Zhang; Beni Varghese-Jacob; Per Ibsen; Alicia Keszler; Nozomu Kurose; Takayuki Nojima; Edward Odell; Lindsey A Criswell; Richard Jordan; John S Greenspan Journal: Arthritis Rheum Date: 2011-07
Authors: Ying-Ting Chen; Stanislav Lazarev; Ahmad F Bahrami; Lisa B Noble; Feeling Y T Chen; Delu Zhou; Marianne Gallup; Mahesh Yadav; Nancy A McNamara Journal: Lab Invest Date: 2012-01-09 Impact factor: 5.662
Authors: Thaya Ramaesh; J Martin Collinson; Kanna Ramaesh; Matthew H Kaufman; John D West; Baljean Dhillon Journal: Invest Ophthalmol Vis Sci Date: 2003-05 Impact factor: 4.799
Authors: Ying-Ting Chen; Karina Nikulina; Stanislav Lazarev; Ahmad F Bahrami; Lisa B Noble; Marianne Gallup; Nancy A McNamara Journal: Am J Pathol Date: 2010-08-09 Impact factor: 4.307
Authors: Shimin Li; Karina Nikulina; Jason DeVoss; Ava J Wu; Erich C Strauss; Mark S Anderson; Nancy A McNamara Journal: Invest Ophthalmol Vis Sci Date: 2008-01 Impact factor: 4.799
Authors: Sara I Van Acker; Zoë P Van Acker; Michel Haagdorens; Isabel Pintelon; Carina Koppen; Nadia Zakaria Journal: Sci Rep Date: 2019-12-23 Impact factor: 4.379
Authors: María Fernanda Suarez; José Echenique; Juan Manuel López; Esteban Medina; Mariano Irós; Horacio M Serra; M Elizabeth Fini Journal: Int J Mol Sci Date: 2021-11-08 Impact factor: 5.923